Expert Review and Recommendations on EGPA Diagnosis and Management

13 Apr 20264 min read0 viewsJournal Feed

GIST

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and heterogeneous immune-mediated disorder in which eosinophilic inflammation, vasculitis, and airway disease coexist in highly variable combinations. In clinical practice, diagnosis remains challenging because no single biomarker reliably captures disease complexity, and therapeutic decisions must still be based on careful integration of clinical, laboratory, imaging, and histopathological findings.

In recent years, EGPA management has evolved from a largely glucocorticoid-based approach toward a more phenotype-oriented strategy that distinguishes eosinophilic and vasculitic manifestations and incorporates targeted biologic therapies. This Perspective discusses current challenges and emerging opportunities in EGPA diagnosis and treatment, with emphasis on early recognition, multidisciplinary assessment, glucocorticoid-sparing strategies, and individualized long-term follow-up.

Specific recommendations are provided on diagnostic orientation, phenotype-driven therapeutic selection, and the practical use of conventional immunosuppressants and anti–IL-5/IL-5R biologics according to disease severity and organ involvement. In addition, we propose a new treatment algorithm intended to support real-world decision-making and to facilitate a more consistent and structured approach to care.

Clinical Editorial

Context and scope

Eosinophilic granulomatosis with polyangiitis (EGPA) is described as a rare, heterogeneous immune-mediated disorder characterized by overlapping eosinophilic inflammation, vasculitis, and airway disease.
Diagnosis remains challenging due to the absence of a single reliable biomarker; clinical, laboratory, imaging, and histopathological data must be integrated for decision-making.

Study design and perspective

The content presents expert perspectives and recommendations rather than new primary trial data.
Emphasis is placed on diagnosis, multidisciplinary assessment, and long-term, phenotype-driven management.

Key themes and recommendations

Phenotype-driven strategy: management increasingly distinguishes eosinophilic from vasculitic manifestations to guide therapy.
Glucocorticoid-sparing approaches: a shift away from solely glucocorticoid-based treatment toward tailored regimens aiming to minimize steroid exposure.
Targeted biologics: incorporation of anti–IL-5/IL-5R therapies alongside conventional immunosuppressants, selected according to disease severity and organ involvement.
Practical guidance: diagnostic orientation, therapeutic selection aligned with phenotype, and structured use of conventional immunosuppressants and biologics in real-world settings.
Algorithmic framework: proposal of a new treatment algorithm to support consistent, decision-ready care pathways.

Limitations and uncertainties

The article acknowledges ongoing challenges in early recognition and the need for multidisciplinary, individualized long-term follow-up.
It notes the evolving therapeutic landscape and the necessity for safer, more effective, and personalized treatment strategies, without presenting new quantitative outcomes.